UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapies and outcomes of congenital hyperinsulinism‐induced hypoglycaemia

Diabetic medicine, 2019-01, Vol.36 (1), p.9-21

2019

Volltextzugriff (PDF)

The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy

Cell, 2014-07, Vol.158 (3), p.564-578

2014

Volltextzugriff (PDF)

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

JAMA : the journal of the American Medical Association, 2021-12, Vol.326 (21), p.2203

2021

Volltextzugriff (PDF)

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

Breast (Edinburgh), 2021-12, Vol.60, p.62-69

2021

Volltextzugriff (PDF)

Trajectories of Injectable Cancer Drug Costs After Launch in the United States

Journal of clinical oncology, 2018-02, Vol.36 (4), p.319-325

2018

Volltextzugriff (PDF)

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals

PLoS genetics, 2019-06, Vol.15 (6), p.e1008181

2019

Volltextzugriff (PDF)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

JAMA oncology, 2021-08, Vol.7 (8), p.1133

2021

Volltextzugriff (PDF)

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

Journal of clinical oncology, 2015-01, Vol.33 (3), p.244-250

2015

Volltextzugriff (PDF)

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

Journal of clinical oncology, 2021-02, Vol.39 (6), p.557-564

2021

Volltextzugriff (PDF)

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2586-2592

2013

Volltextzugriff (PDF)

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Nature medicine, 2020-06, Vol.26 (6), p.878-885

2020

Volltextzugriff (PDF)

Increased visceral sensitivity, elevated anxiety, and depression levels in patients with functional esophageal disorders and non‐erosive reflux disease

Neurogastroenterology and motility, 2021-09, Vol.33 (9), p.e14177-n/a

2021

Volltextzugriff (PDF)

Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles

Cancer research (Chicago, Ill.), 2021-04, Vol.81 (7), p.1639-1653

2021

Volltextzugriff (PDF)

In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels

PloS one, 2011-09, Vol.6 (9), p.e23492-e23492

2011

Volltextzugriff (PDF)

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Gynecologic oncology, 2016-02, Vol.140 (2), p.199-203

2016

Volltextzugriff (PDF)

A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer

JNCI : Journal of the National Cancer Institute, 2017-11, Vol.109 (11)

2017

Volltextzugriff (PDF)

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia

Journal of clinical psychopharmacology, 2020-05, Vol.40 (3), p.240-249

2020

Volltextzugriff (PDF)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Nature communications, 2023-02, Vol.14 (1), p.630-630, Article 630

2023

Volltextzugriff (PDF)

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis

PloS one, 2013-08, Vol.8 (8), p.e70044-e70044

2013

Volltextzugriff (PDF)

LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

Journal of cachexia, sarcopenia and muscle, 2018-10, Vol.9 (5), p.871-879

2018

Volltextzugriff (PDF)

Anti-Müllerian Hormone Is a Marker for Chemotherapy-Induced Testicular Toxicity

Endocrinology (Philadelphia), 2015-10, Vol.156 (10), p.3818-3827

2015

Volltextzugriff (PDF)

Doxorubicin-induced ovarian toxicity

Reproductive biology and endocrinology, 2010-03, Vol.8 (1), p.20-20, Article 20

2010

Volltextzugriff (PDF)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The lancet oncology, 2013-02, Vol.14 (2), p.125-133

2013

Volltextzugriff (PDF)

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2212-2217

2007

Volltextzugriff (PDF)

1 – 25 von 2.522

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR All Journals

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.149)
Mit Volltextzugriff
(1.850)

Publikationsform

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Therapies and outcomes of congenital hyperinsulinism‐induced hypoglycaemia

The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

Trajectories of Injectable Cancer Drug Costs After Launch in the United States

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Increased visceral sensitivity, elevated anxiety, and depression levels in patients with functional esophageal disorders and non‐erosive reflux disease

Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles

In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis

LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

Anti-Müllerian Hormone Is a Marker for Chemotherapy-Induced Testicular Toxicity

Doxorubicin-induced ovarian toxicity

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Aktive Filter

Suchergebnisse filtern